Cerecor Inc. is a Maryland-based biopharmaceutical company comprised of a team of industry experts and leading scientists focused on developing neuroscience drugs that make a difference. We are committed to improving the lives of patients and prioritize underserved segments of common diseases. We exclusively develop products for which human proof-of-concept has been demonstrated and possess biomarkers to guide development. Our clinical strategies employ the latest technologies to improve the signal-to-noise ratio and likelihood of trial success. Our current product opportunities are being developed as first-in-class, best-in-class drug candidates in depression and cognitive disorders, including schizophrenia. With the right partners Cerecor is poised to advance its pipeline of drug candidates with superior efficacy and tolerability thereby helping to ensure better patient outcomes and improved quality of life. Intensive collaborations with established research and development entities, both commercial and academic, enable our aggressive timelines to clinical trials, while also leveraging our resources and capital.